2020
Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis
Bernstein EJ, Jaafar S, Assassi S, Domsic RT, Frech TM, Gordon JK, Broderick RJ, Hant FN, Hinchcliff ME, Shah AA, Shanmugam VK, Steen VD, Khanna D. Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology 2020, 72: 1892-1896. PMID: 32583956, PMCID: PMC7722107, DOI: 10.1002/art.41415.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedFemaleHumansLungLung Diseases, InterstitialMaleMiddle AgedRegistriesRespiratory Function TestsRetrospective StudiesScleroderma, DiffuseSensitivity and SpecificityConceptsDetection of ILDPulmonary function testsInterstitial lung diseaseDiffuse cutaneous SScEarly diffuse cutaneous systemic sclerosisDiffuse cutaneous systemic sclerosisNegative predictive valueCutaneous systemic sclerosisSystemic sclerosisFunction testsLung diseaseDevelopment of ILDDiagnosis of ILDEarly diffuse cutaneous SScRadiographic interstitial lung diseaseInadequate screening toolsEarly systemic sclerosisRetrospective cohort studyCause of deathProspective registrySSc cohortCohort studyVital capacityHRCT imagingHigh risk
2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM, Investigators S. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. The Lancet Respiratory Medicine 2016, 4: 708-719. PMID: 27469583, PMCID: PMC5014629, DOI: 10.1016/s2213-2600(16)30152-7.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseMycophenolate mofetilParallel-group trialLung diseaseOral cyclophosphamidePrimary endpointCyclophosphamide groupGroup trialsPrimary analysisProgressive interstitial lung diseaseMycophenolate mofetil groupUS medical centersTreatment of sclerodermaProgression of sclerodermaPotential clinical effectivenessModified intentionProgressive sclerodermaStudy drugGood tolerabilityHRCT studiesLung functionPulmonary functionTreat analysisTreatment failureVital capacity
2015
Serum Amyloid A Is a Marker for Pulmonary Involvement in Systemic Sclerosis
Lakota K, Carns M, Podlusky S, Mrak-Poljsak K, Hinchcliff M, Lee J, Tomsic M, Sodin-Semrl S, Varga J. Serum Amyloid A Is a Marker for Pulmonary Involvement in Systemic Sclerosis. PLOS ONE 2015, 10: e0110820. PMID: 25629975, PMCID: PMC4321755, DOI: 10.1371/journal.pone.0110820.Peer-Reviewed Original ResearchConceptsSerum amyloid ASystemic sclerosisPulmonary involvementSSc patientsAmyloid AAcute phase protein serum amyloid AEarly diffuse cutaneous systemic sclerosisEffect of SAAInflammatory marker serum amyloid ALevels of SAAElevated serum amyloid AFrequent interstitial lung diseaseDiffuse cutaneous systemic sclerosisLung fibroblastsRecombinant serum amyloid APatient-reported outcome measuresDiffuse cutaneous involvementCutaneous systemic sclerosisEarly-stage diseaseMarkers of inflammationInterstitial lung diseaseNormal lung fibroblastsDose-dependent stimulationHuman pulmonary fibroblastsCutaneous involvement
2012
Text data extraction for a prospective, research-focused data mart: implementation and validation
Hinchcliff M, Just E, Podlusky S, Varga J, Chang RW, Kibbe WA. Text data extraction for a prospective, research-focused data mart: implementation and validation. BMC Medical Informatics And Decision Making 2012, 12: 106. PMID: 22970696, PMCID: PMC3537747, DOI: 10.1186/1472-6947-12-106.Peer-Reviewed Original ResearchConceptsData martElectronic health recordsText data extractionOpen source softwareHealth recordsEnterprise data warehousePulmonary function testsManual chart reviewManual chart abstractionStructured dataSource softwareData warehouseText dataMedical domainTextual reportsScleroderma RegistryCardiac catheterizationChart abstractionChart reviewFunction testsDisease progressionMedical recordsInformatics expertsData extractionDiscrete dataBaseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry
Bae S, Saggar R, Bolster MB, Chung L, Csuka ME, Derk C, Domsic R, Fischer A, Frech T, Goldberg A, Hinchcliff M, Hsu V, Hummers L, Schiopu E, Mayes MD, McLaughlin V, Molitor J, Naz N, Furst DE, Maranian P, Steen V, Khanna D. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Annals Of The Rheumatic Diseases 2012, 71: 1335. PMID: 22307943, PMCID: PMC3398226, DOI: 10.1136/annrheumdis-2011-200546.Peer-Reviewed Original ResearchConceptsRight heart catheterisationPulmonary hypertensionSystemic sclerosisHigh-resolution CTNormal haemodynamicsBaseline characteristicsBorderline mean pulmonary arterial pressureHigh pulmonary vascular resistanceMean pulmonary arterial pressureRight ventricular systolic pressureAbnormal lung physiologyBaseline clinical characteristicsMean pulmonary pressureProspective longitudinal cohortPulmonary vascular resistancePulmonary arterial pressurePulmonary function testsRestrictive lung diseaseVentricular systolic pressureLong-term outcomesElevated mPAPHeart catheterisationVascular resistanceBaseline demographicsClinical characteristics
2011
Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population
Hinchcliff M, Fischer A, Schiopu E, Steen VD. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population. The Journal Of Rheumatology 2011, 38: 2172-2179. PMID: 21844142, PMCID: PMC3230328, DOI: 10.3899/jrheum.101243.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCohort StudiesFemaleHumansHypertension, PulmonaryMaleMiddle AgedPatient SelectionPredictive Value of TestsResearch DesignRespiratory Function TestsScleroderma, SystemicConceptsPulmonary arterial hypertensionIncident pulmonary hypertensionPulmonary hypertensionSystemic sclerosisHigh riskBaseline characteristicsDevelopment of PAHEstimated right ventricular systolic pressureIncident pulmonary arterial hypertensionLeft-side heart diseaseRight ventricular systolic pressureCarbon monoxide diffusing capacityPAH-specific therapyPulmonary Hypertension AssessmentRight heart catheterizationPulmonary venous hypertensionVentricular systolic pressureHigh-risk subjectsInterstitial lung diseaseRecognition of OutcomesSSc-PAHArterial hypertensionHeart catheterizationVenous hypertensionSSc patients